False positive herpes blood tests are far more common than most people realize. Depending on which commercial assay a lab uses, anywhere from about one in eight to nearly one in three positive HSV-2 IgG results can turn out to be wrong, with one widely used platform producing a false positive rate high enough that the U.S. Preventive Services Task Force recommends against routine screening in people without symptoms. The problem is rooted in how these antibody tests work, and understanding it can save you from unnecessary panic, relationship turmoil, and months of worry over a diagnosis that may not be real.
How Often Different Blood Tests Get It Wrong
Not all herpes blood tests perform equally. A 2024 study evaluated three highly automated HSV-2 IgG platforms against the same reference standard and, assuming the estimated U.S. HSV-2 seroprevalence of about 12%, calculated the positive predictive value for each. The Roche assay got it right roughly 96% of the time. Bio-Rad’s assay was correct about 87% of the time, meaning around one in eight positives were false. The DiaSorin assay fared worst: its positive predictive value was only 69%, meaning nearly one of every three positive results would be falsely positive.1PubMed Central. Performance characteristics of highly automated HSV-1 and HSV-2 IgG testing Those numbers assume you are an average American adult being screened. If your actual risk of having HSV-2 is lower than average, the false positive rate climbs even higher.
That last point deserves emphasis. Positive predictive value depends heavily on how common the infection is in the population being tested. When a test with, say, 95% specificity is used in a group where only 5% of people are truly infected, a large share of the positives will be false. This is why the same blood test performs reasonably well in a sexual health clinic where HSV-2 prevalence is high but performs poorly as a screening tool in a general population with lower prevalence.
An older but still influential comparison of crude-antigen commercial tests found even worse concordance with the gold-standard Western blot. Depending on the manufacturer, agreement with Western blot ranged from about 52% to 83%, and specificity for HSV-2 varied wildly, from 54% on one DiaSorin format to 96% on the Focus assay.2American Journal of Clinical Pathology. Inaccuracy of Certain Commercial Enzyme Immunoassays in Diagnosing Genital Infections With Herpes Simplex Virus Types 1 or 2 These older crude-antigen tests have largely been replaced, but some labs still use assays whose specificity leaves a lot to be desired.
The Low-Positive Zone
Most IgG blood tests for HSV-2 report a numerical index value rather than a simple yes or no. Values below 0.9 are considered negative, values above 1.1 are reported as positive, and the slim zone between is equivocal. But there is a much more important dividing line within the “positive” range: results between 1.1 and about 3.5 are far less trustworthy than higher values.
A study that used both the Biokit rapid assay and the University of Washington Western blot to check Focus HerpeSelect results found that only 35% of samples with index values between 1.1 and 3.5 were confirmed as true positives. Compare that with samples scoring above 3.5, where 92% confirmed as genuinely positive.3PubMed Central. Use of “biokit HSV-2 Rapid Assay” to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA In other words, if your index value falls in that low-positive zone, there is roughly a two-in-three chance you do not actually have HSV-2.
The CDC has recommended confirmatory testing for samples in the 1.1 to 3.5 range, and many clinicians follow that guidance. But one research group found that this cutoff misses a substantial number of false positives that fall above 3.5. In their patient population, a meaningful portion of false positive and indeterminate samples had index values above the threshold the CDC set for reflexive confirmatory testing, meaning those patients would have been told they were positive without any second check.4Diagnostic Microbiology and Infectious Disease. Herpes simplex virus type 2 (HSV-2) IgG index values in two immunoassays in relation to HSV-2 IgG inhibition assay results The takeaway is that while a low-positive result should absolutely be confirmed, even a moderately high index value does not guarantee a true positive in every clinical setting.
When HSV-1 Antibodies Fool an HSV-2 Test
One major driver of false positives is cross-reactivity between herpes simplex virus types 1 and 2. HSV-1 (the type most often associated with oral cold sores) and HSV-2 (typically genital) are closely related viruses, and their antibodies look similar enough to confuse certain assays. Older enzyme immunoassays were especially prone to this: one study found that they falsely detected HSV-2 antibodies in anywhere from 8% to 49% of people who actually only had HSV-1.5PubMed. Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2
Modern type-specific assays use a glycoprotein called gG-2 to distinguish HSV-2 from HSV-1, and they perform much better. But cross-reactivity has not been eliminated. Research into an HSV-2 IgG inhibition assay found that very high levels of HSV-1 antibodies can create a complex that interferes with how HSV-2 antibodies bind to the gG-2 antigen on the test, producing a false signal.6PubMed Central. Relationship Between HSV-1 Serostatus and HSV-2 IgG Confirmation Results Using an Inhibition Assay If you have a strong HSV-1 antibody response, your immune system’s reaction to that common virus can nudge an HSV-2 blood test into false positive territory.
A separate study examining discordant results between two HSV-2 IgG assays found that about 18% of samples positive on the DiaSorin platform were negative on the HerpeSelect platform. When a subset of these discordant samples were checked against a composite reference standard, 59 out of 60 turned out to be false positives on DiaSorin, and most of those had low index values between 1.1 and 3.0.7Sexually Transmitted Diseases. Characterization of Serum Samples With Discordant Results in 2 Herpes Simplex Virus Type 2 IgG Assays The pattern reinforces that low-positive results on any single platform should not be accepted at face value.
How Population and Geography Affect Results
The same test can perform very differently depending on where it is used. In a South African cohort where HSV-2 prevalence was high, the Focus HerpeSelect assay had 98% sensitivity but only 61% specificity, and seroprevalence may have been overestimated by as much as 14 percentage points. The Kalon assay was less sensitive at 89% but more specific at 85%.8Sexually Transmitted Infections. Comparison of focus HerpesSelect and Kalon HSV-2 gG2 ELISA serological assays to detect herpes simplex virus type 2 antibodies in a South African population These differences matter because many public health studies rely on serological surveys to estimate how widespread herpes is, and a test that overcounts infections distorts the picture. For an individual patient, the practical consequence is that a positive result from a screening assay in a high-prevalence setting does not carry the same weight as the same result in a low-prevalence setting, even when the same kit is used.
Swab-Based PCR Tests Are Far More Reliable
If blood tests have all these problems, why not just swab the sore? That is exactly what clinicians prefer when an active lesion is present. Polymerase chain reaction testing on a swab specimen detects viral DNA directly, and its accuracy is in a different league from antibody-based blood work.
In a head-to-head comparison, a direct PCR assay detected about 95% of true HSV-positive swabs, while a laboratory-developed real-time PCR method caught about 98%. Older methods like viral culture and direct fluorescent antibody testing lagged behind at roughly 86% to 88% sensitivity.9PubMed Central. Comparison of Simplexa HSV 1 & 2 PCR with culture, immunofluorescence, and laboratory-developed TaqMan PCR for detection of herpes simplex virus in swab specimens Another evaluation of several real-time PCR assays found sensitivity ranging from 98% to 100% and specificity at a full 100%, compared with just 37% sensitivity for traditional culture.10PubMed. Evaluation of real-time polymerase chain reaction assays for the detection of herpes simplex virus in swab specimens
The catch is that a swab only works when there is something to swab. Between outbreaks, or in people who have never had a noticeable sore, there is no lesion to test. That is why blood tests exist in the first place: they detect antibodies your immune system has produced, which persist whether or not you are having symptoms. But the trade-off for that convenience is a much higher chance of a wrong answer, particularly a false positive.
Point-of-Care Rapid Tests
Rapid, finger-prick-style tests designed for clinic or field use add another dimension to the accuracy question. A lateral-flow immunochromatographic device tested against HerpeSelect ELISA showed 100% sensitivity and about 97% specificity, though it did exhibit cross-reactivity with HSV-1 antibodies in roughly 3% of samples, and occasional false signals from Epstein-Barr virus antibodies as well.11PubMed Central. Rapid, sensitive, and specific lateral-flow immunochromatographic point-of-care device for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in serum and whole blood
Not all rapid tests are created equal. A validation study in rural Tanzania tested two point-of-care devices and found dramatically different results. One brand had only 30% sensitivity but 100% specificity, meaning it would miss most true infections but almost never produce a false positive. The other had roughly 70% sensitivity and 87% specificity, striking a different balance between catching infections and avoiding false alarms.12PubMed Central. Validation of rapid point-of-care tests for herpes simplex virus-type 2 in rural Tanzania These numbers illustrate that “rapid test” is not a single category. Performance depends heavily on the manufacturer, the setting, and the population being tested.
Why Routine Screening Is Not Recommended
Given all of the above, it is no surprise that major health authorities recommend against routine herpes blood testing in people who have no symptoms. The USPSTF issued a recommendation against screening for HSV-2 in asymptomatic adolescents and adults, citing the high false positive rate of available serologic tests along with the anxiety and relationship disruption that come with a herpes diagnosis.13JAMA. Serologic Screening for Genital Herpes Infection The CDC’s 2021 STI treatment guidelines echo this approach, calling it reasonable for people with few lifetime sexual partners, no known HSV-2-positive partners, and no genital symptoms.14Clinical Infectious Diseases. Diagnosis and Management of Genital Herpes: Key Questions and Review of the Evidence for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines
This is unusual. For most sexually transmitted infections, public health messaging encourages broad screening. Herpes is the exception specifically because current blood tests are not good enough to screen low-risk populations without generating an unacceptable number of false positives. The harms are not hypothetical: a systematic review for the USPSTF found adequate evidence that false positive results lead to psychosocial distress and additional costs from confirmatory testing, and rated the overall harms of screening as at least moderate.15JAMA. Serologic Screening for Genital Herpes: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
What To Do if You Get a Positive Blood Test
If you already have a positive HSV-2 IgG result and are trying to figure out what it means, the first thing to look at is the index value. Ask your provider or lab for the actual number, not just “positive” or “negative.” If the value falls between 1.1 and 3.5, confirmatory testing is strongly warranted. The University of Washington’s Western blot has long been considered the gold standard for confirmation, and some labs also offer an HSV-2 IgG inhibition assay that can help sort true positives from false ones.
Even if your index value is above 3.5, you are not necessarily in the clear. As the inhibition assay research showed, false positives can occur above that threshold, especially in certain patient populations. If you have never had symptoms, have a low-risk sexual history, or have reason to believe HSV-1 antibodies could be muddying the picture, discussing confirmatory testing with your clinician is reasonable regardless of the index value.
A comparison of immunoblot, ELISA, and chemiluminescent immunoassay methods found that for HSV-2, immunoblot achieved 100% specificity with about 98% sensitivity, while ELISA specificity was around 98% and chemiluminescent assay specificity was close to 100%.16PubMed Central. Comparison of commercial methods of immunoblot, ELISA, and chemiluminescent immunoassay for detecting type-specific herpes simplex viruses-1 and -2 IgG Newer chemiluminescent platforms, in other words, may offer a practical alternative to Western blot for confirmation, especially as the University of Washington Western blot has faced intermittent availability issues in recent years.
The Direct-to-Consumer Testing Problem
The rise of online lab testing services has made it easy for anyone to order an HSV blood panel without a clinician visit. You pay out of pocket, go to a draw station, and get your results by email. This sounds empowering, but it collides directly with everything we know about false positives in low-risk populations.
When someone with a low pretest probability of infection orders a herpes test, the math tilts sharply toward false positives. There is no clinician to explain that a low-positive index value needs confirmation. There is no context about which assay the lab used. The result arrives as a number on a screen, and many people understandably interpret any positive as a definitive diagnosis. Researchers in infectious disease have flagged this as a significant concern, noting that direct-to-consumer testing for infections where pretest probability matters can lead to misdiagnosis and overdiagnosis.
If you have already gone this route and received a positive result, treat it as a preliminary finding. Bring the result to a healthcare provider who can assess your risk factors, order the right confirmatory test, and interpret the outcome in context. A standalone lab number, no matter how authoritative it looks on a printout, is not a diagnosis.
Herpes Testing During Pregnancy
Pregnancy adds urgency to the question of testing accuracy because a first-episode genital herpes infection near the time of delivery can pose serious risks to the newborn. A decision analysis of type-specific screening in pregnancy found that universal screening would require treating nearly 3,850 women to prevent one case of neonatal death or severe disease from HSV, while targeted screening of high-risk women brought that number down to about 2,280.
The math here highlights the tension between wanting to catch every dangerous case and the reality that most positive screening results in a general pregnant population will be in women with long-standing infections who pose minimal transmission risk to their babies. False positives in this context can lead to unnecessary cesarean deliveries, antiviral treatment, and significant maternal anxiety. Current practice generally favors clinical assessment and targeted testing over universal serological screening in pregnancy, though practices vary by institution and clinical circumstance.
How Test Technology Is Shifting
The landscape is not static. The 2024 evaluation of newer automated platforms found that the Roche HSV-2 IgG assay achieved a positive predictive value above 96% at the estimated U.S. population prevalence, a substantial improvement over older platforms.1PubMed Central. Performance characteristics of highly automated HSV-1 and HSV-2 IgG testing If assays like this become the default in clinical labs, the false positive problem shrinks considerably, though it does not disappear entirely. No serological test will achieve the near-perfect specificity of a PCR swab, because detecting antibodies is inherently messier than detecting viral DNA.
Inhibition assays, which work by pre-incubating the sample with HSV antigen to see if the signal drops, offer another tool for resolving ambiguous results without resorting to Western blot. These are increasingly available and can be reflexively run on the same sample, saving the patient a second blood draw. Their broader adoption would help close the gap between a screening result and a confident diagnosis, particularly for samples that land in the low-positive zone or come from patients with strong HSV-1 antibody responses.
For now, though, the practical reality is that if you are tested for herpes with a blood test and receive a positive result, the chance it is wrong ranges from trivial to substantial depending on the assay, your index value, and your underlying risk. Knowing this does not mean ignoring a positive result. It means insisting on the right follow-up before accepting a life-altering label.